Monday, September 18, 2017

New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes

Sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes, research indicates. Sotagliflozin has shown promise in improving glucose control without any increase in severe hypoglycemia or diabetic ketoacidosis compared to insulin alone.

from Diet and Weight Loss News -- ScienceDaily http://ift.tt/2xLCIXX

No comments:

Post a Comment